The Decline of Science In the Pandemic
Early in the pandemic there was a widespread belief that science would be our salvation. With the help of science we would be spared the worst consequences, such as occurred during the 1918 Spanish flu pandemic. A vaccine would arrive, reliably, after a few hard months of research, and in short order the problem would...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 16, 2020 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics COVID-19 pandemic science Source Type: blogs

A COVID-19 Cardiac MRI Study: What Went Wrong?
We still don’t know what COVID-19 is doing to the heart or how we should be investigating it and treating it. Last month JAMA Cardiology published a German cohort study of 100 patients recently recovered from COVID-19… A number of striking problems with the study were noted on Twitter…...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 25, 2020 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes COVID-19 MRI scientific misconduct Source Type: blogs

Don ’ t Confuse the Art and Science of Medicine: PCI vs CABG for Left Main Disease
It is often said that medicine is both an art and a science. In an imperfect world this is both inevitable and desirable. But it is extremely important that the two should not be confused with each other. In particular, because the “science” side of the equation has achieved overwhelming prestige and authority, it is...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 20, 2020 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics CABG guidelines left main disease LMCA PCI Source Type: blogs

News About CardioBrief and CVCTCardioBrief
Note to readers: After a period of inactivity CardioBrief is coming back, but with some big differences. This website, CardioBrief.Org, will remain my personal website. A new website, CVCTCardiobrief.com, will be the new home for my “professional” blogging activities. To develop this website I have joined forces with the global CVCT Forum. I look forward to...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 17, 2020 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events CVCT Source Type: blogs

No, CRISPR Is Not Going To ‘ Cure ’ Heart Disease
No, CRISPR gene editing technology is not going to “cure” heart disease. But a New York Times story by Gina Kolata on an extremely early study in animals prominently plays up just this extremely unlikely claim. The Times story is based on a press release issued by Verve Therapeutics, a new biotechnology company founded by Sekar Kathiresan, an influential cardiologist and genomic...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - June 30, 2020 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes CRISPR gene editing hype journalism LDL PCSK9 Source Type: blogs

What Can We Learn From The Apple Heart Study?
Do we ever learn from our past mistakes? For many years we believed that technology was an inevitable force for good. It would give us instant access to a near infinite amount of information and allow us to easily and instantly connect with nearly anyone on earth. What could go wrong? The answer is that...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 14, 2019 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes $AAPL Apple Apple Watch technology wearables Source Type: blogs

Health Hype Alert: Beware the Apple Watch
This morning STAT published an Op-Ed piece I wrote about the Apple Watch. Here’s how it starts: Set your smartwatch alarm. You’re about to be barraged by tons of hype about the health benefits of the Apple Watch. Unfortunately, it won’t include essential information and data that can put these claims in proper perspective. Last year,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 15, 2019 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Apple Watch atrial fibrillation screening Source Type: blogs

The Simple Truth About Fake Medical News
Note: This is a slightly revised version of a talk I delivered at the recent CVCT Conference in Washington, DC.  Why are we vulnerable to fake news and why is it so hard to get rid of it? This is a complex question, but one important factor is that fake news delivers clear and simple...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 22, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized fake medical news fake news media Source Type: blogs

Questions Raised About Invokana Label Expansion For CV Risk Reduction
It hasn’t received a lot of media attention but on Tuesday the FDA approved an expansion of the canagliflozin (Invokana, Janssen) label to include a reduction in the risk of heart attack, stroke, or CV death in adults with type 2 diabetes and established CV disease. Canagliflozin, an oral SGLT2 inhibitor, thus becomes the third...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 1, 2018 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics CVOT Invokana Source Type: blogs

Cardiovascular Research Foundation Blocks Press Access to TCT2018 Meeting
(Updated) The Cardiovascular Research Foundation (CRF) has denied press credentials for the TCT2018 meeting to a legitimate, fully accredited journalist. The meeting, which starts this weekend in San Diego, is the premiere interventional cardiology meeting. Legitimate journalists are routinely granted access to cover medical and scientific meetings. By any standard, Cat Ferguson is a respected and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 20, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics CRF journalism TCT meeting TCT2018 Source Type: blogs

Right Wing Minority Rule
The US is not perfect but until recently it has always moved, inexorably, if slowly and fitfully, in the general direction of justice and greatness. The best and undeniable example of this in recent times is the election of Barack Obama, something which would have been unthinkable at any other time in our history. But...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 6, 2018 Category: Cardiology Authors: Larry Husten Tags: Uncategorized GOP politics Trump Source Type: blogs

What Happens When A Healthy 86-Year-Old Gets Atrial Fibrillation
Editor’s note: 86-year-old Nina Mishkin was still healthy and active when she went to Dublin, Ireland last September. After she returned home she developed atrial fibrillation, and then much more. “I never felt particularly vulnerable and fragile before,” she writes. “Now I do… It’s a different universe I inhabit.” I am grateful to Nina for giving...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 30, 2018 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Heart Rhythms People, Places & Events Policy & Ethics AF geriatrics old age pacemaker patient perspective Source Type: blogs

Lancet Paper Adds To Evidence That Reducing Salt To Very Low Levels May Be Dangerous
A new paper from a very large ongoing observational study offers additional and more powerful evidence that dramatic reductions in salt consumption may not be beneficial and might even prove harmful. The finding supports growing criticism that current guideline recommendations to dramatically lower salt intake in the general population may be misguided. The study also...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 10, 2018 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes guidelines potassium PURE salt sodium Source Type: blogs

No, A Big NIH Trial Did Not Show That Lowering Blood Pressure Will Prevent Dementia
It’s “breakthrough” time again. News reports out of the Alzheimer’s Association International Conference (AAIC) this week have been relentlessly upbeat and positive about findings from the NIH’s SPRINT MIND study. The message: aggressive blood pressure control can help protect the brain. But unless you look very carefully at the news reports and “expert” statements you won’t...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 26, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized Alzheimer's blood pressure dementia NIH SPRINT SPRINT MIND Source Type: blogs

Warning: Pirate Sites Are Now Kidnapping Doctors Booking Hotels At Medical Meetings
Pirates are attacking interventional cardiology meetings. Interventional cardiologists planning to attend the upcoming TCT meeting should be aware that at least one pirate web site is out to dupe them. (The annual TCT meeting, which runs this year in San Diego from September 21-25, is the première meeting for interventional cardiologists.) The pirates are trying...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 24, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics fake advertising fraud hotel rooms internet schemes pirate sites TCT TCT meeting Source Type: blogs

If You Look For Atrial Fibrillation You Will Find Atrial Fibrillation
If you look hard to find people who have atrial fibrillation (AF) you will in fact find people who have atrial fibrillation, a new paper published in JAMA shows. But the paper offers no evidence whatsoever that the new diagnosis improves outcomes in these people, though it does find that the diagnosis leads to increased use of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 10, 2018 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized AF atrial fibrillation ECG monitoring screening Source Type: blogs

1 in 4 Cardiovascular Patients in Low Income Families Have Significant Financial Pain
Editor’s note: The following guest post is by Khurram Nassir, a cardiologist at the Yale University School of Medicine. He is the senior author of a new paper in JAMA Cardiology, “Association of Out-of-Pocket Annual Health Expenditures With Financial Hardship in Low-Income Adults With Atherosclerotic Cardiovascular Disease in the United States.” 1 in 4 Cardiovascular...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 4, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics financial hardship Source Type: blogs

On Cannibals And Cardiologists
Everyone knows that cannibalism was practiced widely in pre-Colombian Mexico. Go online and you will quickly learn that 15,000 to 20,000 Aztecs were sacrificed each year. This “fact” colors our view of that civilization, and makes it a bit easier to give a pass to the conquistadors who, for all their own rapacity, brought “civilization”...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - June 21, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics ICDs overuse stents Source Type: blogs

Outsiders Swoop In Vowing To Rescue Rural Hospitals Short On Hope — And Money
Editor’s note: the following article is reprinted with permission from Kaiser Health News. Links to previous CardioBrief coverage of the laboratory scandal story can be found at the bottom of the page. by Barbara Feder Ostrov, Kaiser Health News CEDARVILLE, Calif. — Beau Gertz faced a crowd of worried locals at this town’s senior center,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - June 5, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics HDL Lab lab scandal lab tests laboratory tests Source Type: blogs

New ORBITA Findings May Offer Modest Symptomatic Pain Relief To Interventional Cardiologists
New data presented at EuroPCR from the much debated ORBITA trial may provide some modest temporary lessening of the pain felt by interventional cardiologists in response to the initial negative ORBITA findings. But the pain relief is likely to be only temporary, and might even be fairly compared to a placebo effect, since the major...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 22, 2018 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics ORBITA PCI sham controls stable angina stents Source Type: blogs

NIH Halts Large Cardiovascular Inflammation Reduction (CIRT) Trial
The NHLBI has put an early stop to the large Cardiovascular Inflammation Reduction (CIRT) Trial. The NHLBI action was based on a recommendation from the trial’s Data and Safety Monitoring Board. The action was not based on any substantive safety concerns. “Sometime in late March or early April the NHLBI informed me that there were no substantive...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 21, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics CANTOS inflammation methotrexate Source Type: blogs

Salt War Opponents Unite In Call For Randomized Trial In Prisons
The opposing camps in the salt wars don’t agree on much, but they have now found common ground in their belief that the only way to settle the salt question is with a large randomized controlled trial. Further, they now agree that it would be nearly impossible to perform such a trial in the real...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 21, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes guidelines outcomes trials RCTs salt sodium Source Type: blogs

American Heart Association Venture Capital Fund Sparks Criticism
(Updated) The American Heart Association has announced that it has launched a $30 million venture capital fund “designed to spur healthcare innovation in heart disease and stroke care.” The AHA said that the Cardeation Capital fund will be funded by the AHA and co-investors Philips and UPMC. The fund “will invest in emerging healthcare companies that can...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 17, 2018 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized american heart association COI conflict of interest venture capital Source Type: blogs

CABANA: No Outcomes Benefit In First Big Trial Of AF Ablation
(Updated) Catheter ablation for atrial fibrillation (AF) produced no significant improvement in clinical outcomes in a large and important new clinical trial. CABANA is the first and long anticipated randomized controlled trial of AF ablation in the more than two decade long history of the procedure. The results will likely spark an intense controversy in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 10, 2018 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms People, Places & Events Policy & Ethics atrial fibrillation CABANA catheter ablation NIH RCTs Source Type: blogs

More Controversy Over Major Cardiology Clinical Trial
Think about this: A new article reports that a major NIH-funded trial runs into trouble. The article raises all sorts of fundamental questions about our ability to perform meaningful clinical research. But instead of expressing concern about these legitimate problems, medical leaders ignore these questions and instead focus their ire and criticism on the article authors,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 30, 2018 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes clinical trials ischemia NIH PCI primary endpoint revascularization stents Source Type: blogs

Cardiology World Erupts Into Controversy Over Change In Major Clinical Trial
As a major clinical trial in cardiology nears completion it has provoked a storm of criticism and controversy. The brouhaha erupted in response to a late change to one of the most important— and already controversial— trials in cardiovascular medicine. The NIH-funded ISCHEMIA trial was designed back in 2011 to provide a definitive answer to...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 18, 2018 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized clinical trials ischemia NIH ORBITA primary endpoint stents Source Type: blogs

More Bad News For The Once Promising Bioresorbable Stent
(Updated) –Problems for the Absorb BVS stent just won’t disappear Bad news for the Absorb BVS stent continues to accumulate, though defenders of the device keep looking for a silver lining. When it was approved in the US last summer the novel device appeared to have a bright future, with many prominent interventional cardiologists predicting...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 31, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Abbott ABSORB bioresorbable stent BVS DAPT stent throb Source Type: blogs

Interventional Cardiologists Face Major Obstruction In Treatment Of Total Blockages
–Deep divisions over how CTO patients should be treated. In recent years ambitious interventional cardiologists have started to perform PCI on chronic total occlusions (CTOs), though these lesions have long been recognized as among the most difficult to successfully treat. Many other physicians, including some prominent interventional cardiologists, have expressed grave concerns about this expansion...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 29, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics chronic total occlusion CTO Source Type: blogs

Controversial Pharma CEO To Chair AHA Charity Ball
–The Wizard of Oz-themed ball seeks to raise $2 million on the yellow brick road. The American Heart Association’s annual Heart & Stroke Ball will be chaired by John Thero, the CEO of Amarin Corporation, the controversial pharmaceutical company. Amarin manufactures the prescription fish oil product Vascepa for which it is aggressively seeking an expanded indication...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 24, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes AHA Amarin charity conflict of interest Vascepa Source Type: blogs

TV Ads Pushed Inappropriate Use of Testosterone
–Study: prescriptions spiked in direct response to blizzard of ‘Low T’ ads Television ads for testosterone products were highly successful, leading to dramatic increases in the number of men taking testosterone drugs, according to a new study published in the Journal of the American Medical Association. J. Bradley Layton (University of North Carolina, Chapel Hill)...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 21, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes advertising DTCA low-T testosterone Source Type: blogs

Another HDL Therapy Crashes and Burns
–Failure of pre-beta HDL mimetic puts another nail in the HDL coffin Once again, an HDL-inspired therapy has failed when put to the test in a clinical trial. Although there are still ongoing trials with other HDL-related therapies, most experts now feel that it is time for the field to turn its attention elsewhere and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 19, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes cholesterol HDL triglycerides Source Type: blogs

Ebbinghaus Study May Help Refute Doctor Google
–No neurocognitive adverse effects linked to very low LDL levels Reaching very low LDL levels with a PCSK9 inhibitor was not associated with any increase in neurocognitive adverse events, according to the largest and most rigorous study to assess the topic to date. Small and preliminary studies have raised concerns over the possibility of the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 18, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes adverse events evolocumab Fourier neurocognitive PCSK9 Repatha Source Type: blogs

Novel Drug Delivers Long Term Cholesterol Reduction
A novel drug that dramatically lowers LDL cholesterol and needs to be administered only a few times a year has reached a new milestone. Positive results from a phase II study with the drug, now known as inclisiran, were reported at the American College of Cardiology meeting in Washington, DC and published simultaneously in the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 17, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes cholesterol inclisiran LDL Medicines Company PCSK9 Source Type: blogs

FOURIER Shows New Cholesterol Drugs Work, But Are They Worth It?
–Doctors and patients now must wrestle with a modestly effective but expensive drug. As it turns out the PCSK9 inhibitor saga ends not with a bang but a whimper. The results of the highly anticipated FOURIER trial show that the drugs work, though not as powerfully as many had hoped and expected. The question now...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 17, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol evolocumab LDL lipids PCSK9 Repatha Source Type: blogs

Scott Gottlieb ’ s Sham Ideology Rejects Clinical Trials
Donald Trump has nominated Scott Gottlieb to be the next FDA Commissioner. To his credit, Gottlieb is not certifiably crazy like several of the other candidates who were reported to be under consideration for the job. But he is is a deeply conservative ideologue who is determined to reduce the government’s role in healthcare. On two occasions in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 14, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Uncategorized clinical trials FDA hypertension renal denervation Scott Gottlieb Trump Wall Street Journal Source Type: blogs

For Scott Gottlieb, Business Trumps Health
Donald Trump has nominated Scott Gottlieb to be the next FDA Commissioner. To his credit, Gottlieb is not certifiably crazy like several of the other candidates who were reported to be under consideration for the job. But he is is a deeply conservative ideologue who is determined to reduce the government’s role in healthcare. On two occasions in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 14, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics American Enterprise Institute CMS FDA Scott Gottlieb TAVR Trump Source Type: blogs

Has Nutrition Science Been Poisoned?
–The inevitable weaknesses of observational and diet studies “Science is the great antidote to the poison of enthusiasm and superstition,” Adam Smith wrote more than 200 years ago. Unfortunately, it often seems as if the science of nutrition has itself been poisoned. Two recently published papers illustrate this problem. Nutrition and Mortality A good example of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 9, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes association causality diet nutrition Source Type: blogs

Call For More Calcium Screening Gets Pushback
–But a zero calcium score can be useful to avoid statins, some argue Coronary artery calcium (CAC) scans should be widely used in routine clinical practice to improve the detection of coronary disease in people without known disease, according to the authors of a new review in JACC: Cardiovascular Imaging. But many experts urged caution,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 6, 2017 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes calcium coronary artery calcium CV risk Framingham risk assessment screening Source Type: blogs

Top Cardiologist Blasts Nutrition Guidelines
–Salim Yusuf says new evidence fails to support many major diet recommendations. One of the world’s top cardiologists says that many of the major nutrition guidelines have no good basis in science. “I’m not a nutrition scientist and that may be an advantage because every week in the newspaper we read something is good for...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 27, 2017 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes carbs diet fats guidelines nutrition salt Source Type: blogs

After Yet Another Failure, Stem Cell Leaders Double Down
–Could repeated doses of stem cells turn the tide of negative trials? Despite an unrelieved history of negative trials, stem cell leaders continue to defend their field. In response to the failure of yet another cardiac stem clinical trial, Roberto Bolli, a prominent leader in the field, argued that it’s time for a “paradigm shift” in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 21, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics searching for the pony Stem cell stem cell therapy Source Type: blogs

International Experts Call Salt Guidelines Far Too Restrictive
A broad group of international experts are recommending a far more modest and less draconian approach to sodium restriction than current U.S. and international guidelines. In a new paper, published online in the European Heart Journal, they also focused on the broad gaps of knowledge in the field and drew attention to the paucity of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 14, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes evidence guidelines hypertension salt sodium Source Type: blogs

Enormous Rivaroxaban Study Stopped Early For ‘ Overwhelming Efficacy ’
(Updated) –Oral anticoagulant reduced CV events in patients with coronary and peripheral disease. The very large COMPASS study has been stopped early for “overwhelming efficacy,” according to a press release issued by Bayer AG and Janssen, manufacturers of rivaroxaban (Xarelto). The phase 3 trial randomized 27,402 patients with coronary artery disease (CAD) and peripheral artery...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 8, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Anticoagulant CAD NOAC PAD rivaroxaban Source Type: blogs

New Questions Raised About SPRINT
More questions are being raised about SPRINT, the enormous NIH-funded blood pressure lowering trial. Two recent developments will likely add more obstacles to the already difficult task of applying the results of the trial in the real world. Even before the full results of the trial were first made public the NIH and the SPRINT...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 8, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes blood pressure data sharing hypertension open data SPRINT Source Type: blogs

27,000 Patient PCSK9 Inhibitor Trial Meets Main Endpoints
–Cardiovascular outcomes finally available for PCSK9 inhibitors. Amgen announced on Thursday afternoon that the FOURIER trial had met both its primary composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the even more rigorous key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke). The company also...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 2, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Amgen cholesterol CVOT evolocumab PCSK9 statins Source Type: blogs

In Which I Go Under The Knife And Learn About Medicine In The Real World
I’m not a doctor but I thought I knew something about anticoagulation. Over the course of a career covering cardiology I’ve written countless stories about heparin, warfarin, the low molecular weight heparins, and the new oral anticoagulants. So when I had bilateral total knee replacement a few weeks ago I thought I knew what to...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 27, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics anticoagulation aspirin Evidence-based medicine Lovenox total knee replacement Xarelto Source Type: blogs

Long Unsuccessful Heart Failure Drug Once Again At Center Of Controversy
–The long, strange 30-year journey of BiDil. It’s been buried in the avalanche of related news but there’s an interesting and somewhat bizarre cardiology angle to the debate over Trump’s nomination of Tom Price to be the next HHS Secretary. ProPublica reported on Friday that last summer Price went to bat for the makers of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 23, 2017 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Uncategorized ACE inhibitors BiDil conflict of interest HHS Tom Price Source Type: blogs

Screen-And-Treat to Prevent Diabetes Doomed to Fail
Screening must be supplemented by broader public health approaches. Screen and treat strategies to prevent type 2 diabetes are doomed to failure, according to a large new systematic review and meta-analysis published in The BMJ.  Instead, the authors said and outside experts agreed, any effort to combat the already enormous and still growing problem of type 2...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 5, 2017 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes glucose metformin population measures Public health screening Source Type: blogs

2016: Great Year Or Greatest Year Ever?
Editor’s note: Once again Larry was too depressed to write the 2016 yearly review. (Actually, he’s hiding under his bed.) Veteran healthcare journalist and eternal optimist Candide Corn has again kindly agreed to take over the task this year. Candide’s motto is “all is for the best in the best of all possible worlds.” What a great year!...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 21, 2016 Category: Cardiology Authors: Larry Husten Tags: Classics Interventional Cardiology & Surgery People, Places & Events Policy & Ethics year in review Source Type: blogs

More Shots Fired in ‘ Sugar War ’
–Industry-sponsored study questions current guidelines on dietary sugar. Dietary guidelines relating to sugar— all of which recommend significant reductions in sugar intake— are based on weak evidence and are not trustworthy, according to a systematic review published in Annals of Internal Medicine. But an accompanying editorial points out that the systematic review is itself not...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 20, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Coca Cola dietary guidelines nutrition sugar Source Type: blogs

Novartis Withdraws Support For Controversial Entresto Contest
(Updated) Novartis will no longer sponsor a contest designed to support the publication of peer review articles about Entresto, the company’s important new heart failure drug. The contest is taking place on Cureus, an open access journal, publishing platform, and vehicle for industry-sponsored content. The contest offered $10,000 in rewards for articles supporting a recent...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 19, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics contest Entresto Guideline LCZ Novartis Source Type: blogs